Nucleophilic Antibodies: Characterization and Induction

亲核抗体:表征和诱导

基本信息

  • 批准号:
    8015976
  • 负责人:
  • 金额:
    $ 45.44万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2007
  • 资助国家:
    美国
  • 起止时间:
    2007-02-01 至 2013-01-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): We seek to: (a) characterize the functional properties of antibodies (Abs) that bind HIV gp120 with irreversible character and catalyze the cleavage of the protein, (b) study the structural basis of these activities, and (c) study the neutralizing IgA responses induced by mucosal immunization with electrophilic gp120 analogs. The irreversibly binding Abs were raised by immunization with an electrophilic analog of full- length monomer gp120 and recognize two conserved peptide regions, one of which is a segment of the superantigenic site of gp120. The proteolytic Abs are naturally occurring human Abs that also recognize the superantigenic peptide region. Nucleophilic amino acids in the Ab combining sites are hypothesized to form dead-end irreversible complexes with gp120 or a covalent reaction intermediate that proceeds into the catalytic pathway, depending on the presence of accessory structural elements. As the structures of viral and monomer gp120 are different, we propose further study of Ab functional properties using intact virions as substrates. Neutralization studies will be done using peripheral blood mononuclear cells infected with diverse primary HIV isolates. Structural studies will entail identification of nucleophilic residues by crystallography, biochemical mapping and site-directed mutagenesis. Crystallography will also identify additional constituents of the nucleophilic site, the presence of the accessory catalytic structures (e.g., the oxyanion hole and water interacting residues), and the noncovalent binding contacts responsibe for the epitope specificity of the Abs. The Abs will be studied in unliganded state and complexed covalently to their peptide or peptide analog epitopes. To study whether the innate ability of IgAs to cleave gp120 can be recruited for defense against the virus, we will attempt to amplify the synthesis of neutralizing, proteolytic IgAs by mucosal immunization using our existing and novel electrophilic gp120 analogs. From these studies, we hope to identify the strengths and weaknesses of the Abs and immunogens relevant to HIV vaccination and therapy.
描述(由申请人提供):我们寻求:(a)表征以不可逆特征结合HIV gp120并催化蛋白质裂解的抗体(Ab)的功能特性,(B)研究这些活性的结构基础,和(c)研究由亲电子gp120类似物粘膜免疫诱导的中和伊加应答。通过用全长单体gp120的亲电类似物免疫产生不可逆结合Ab,并且识别两个保守肽区,其中一个是gp120的超抗原位点的区段。蛋白水解Ab是也识别超抗原肽区的天然存在的人Ab。在抗体结合位点的亲核氨基酸被假设为形成死端不可逆复合物与gp120或共价反应中间体,进入催化途径,这取决于存在的辅助结构元件。由于病毒和单体gp120的结构不同,我们建议使用完整的病毒粒子作为底物进一步研究抗体的功能特性。将使用感染不同原代HIV分离株的外周血单核细胞进行中和研究。结构研究将需要通过晶体学、生物化学作图和定点诱变鉴定亲核残基。结晶学还将鉴定亲核位点的其它成分、辅助催化结构的存在(例如,含氧阴离子空穴和水相互作用残基),以及非共价结合接触,其响应Ab的表位特异性。将在未配体状态下研究Ab,并与其肽或肽类似物表位共价复合。为了研究IgA切割gp120的先天能力是否可以被招募用于防御病毒,我们将尝试使用我们现有的和新的亲电子gp120类似物通过粘膜免疫来扩增中和、蛋白水解IgA的合成。通过这些研究,我们希望确定与HIV疫苗接种和治疗相关的抗体和免疫原的优势和劣势。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Sudhir Paul其他文献

Sudhir Paul的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Sudhir Paul', 18)}}的其他基金

Efficacious and safe antibody catalyzed amyloid beta clearance
有效且安全的抗体催化β淀粉样蛋白清除
  • 批准号:
    8728715
  • 财政年份:
    2010
  • 资助金额:
    $ 45.44万
  • 项目类别:
Efficacious and safe antibody catalyzed amyloid beta clearance
有效且安全的抗体催化β淀粉样蛋白清除
  • 批准号:
    7984646
  • 财政年份:
    2010
  • 资助金额:
    $ 45.44万
  • 项目类别:
Efficacious and safe antibody catalyzed amyloid beta clearance
有效且安全的抗体催化β淀粉样蛋白清除
  • 批准号:
    8527652
  • 财政年份:
    2010
  • 资助金额:
    $ 45.44万
  • 项目类别:
Efficacious and safe antibody catalyzed amyloid beta clearance
有效且安全的抗体催化β淀粉样蛋白清除
  • 批准号:
    8320914
  • 财政年份:
    2010
  • 资助金额:
    $ 45.44万
  • 项目类别:
Efficacious and safe antibody catalyzed amyloid beta clearance
有效且安全的抗体催化β淀粉样蛋白清除
  • 批准号:
    8144329
  • 财政年份:
    2010
  • 资助金额:
    $ 45.44万
  • 项目类别:
Nucleophilic Antibodies: Characterization and Induction
亲核抗体:表征和诱导
  • 批准号:
    7341060
  • 财政年份:
    2007
  • 资助金额:
    $ 45.44万
  • 项目类别:
Nucleophilic Antibodies: Characterization and Induction
亲核抗体:表征和诱导
  • 批准号:
    7577404
  • 财政年份:
    2007
  • 资助金额:
    $ 45.44万
  • 项目类别:
Nucleophilic Antibodies: Characterization and Induction
亲核抗体:表征和诱导
  • 批准号:
    7230575
  • 财政年份:
    2007
  • 资助金额:
    $ 45.44万
  • 项目类别:
Nucleophilic Antibodies: Characterization and Induction
亲核抗体:表征和诱导
  • 批准号:
    7759599
  • 财政年份:
    2007
  • 资助金额:
    $ 45.44万
  • 项目类别:
Proteolytic Antibody HIVcides
蛋白水解抗体杀艾滋病剂
  • 批准号:
    7286844
  • 财政年份:
    2006
  • 资助金额:
    $ 45.44万
  • 项目类别:

相似海外基金

Construction of affinity sensors using high-speed oscillation of nanomaterials
利用纳米材料高速振荡构建亲和传感器
  • 批准号:
    23H01982
  • 财政年份:
    2023
  • 资助金额:
    $ 45.44万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Affinity evaluation for development of polymer nanocomposites with high thermal conductivity and interfacial molecular design
高导热率聚合物纳米复合材料开发和界面分子设计的亲和力评估
  • 批准号:
    23KJ0116
  • 财政年份:
    2023
  • 资助金额:
    $ 45.44万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Platform for the High Throughput Generation and Validation of Affinity Reagents
用于高通量生成和亲和试剂验证的平台
  • 批准号:
    10598276
  • 财政年份:
    2023
  • 资助金额:
    $ 45.44万
  • 项目类别:
Development of High-Affinity and Selective Ligands as a Pharmacological Tool for the Dopamine D4 Receptor (D4R) Subtype Variants
开发高亲和力和选择性配体作为多巴胺 D4 受体 (D4R) 亚型变体的药理学工具
  • 批准号:
    10682794
  • 财政年份:
    2023
  • 资助金额:
    $ 45.44万
  • 项目类别:
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
  • 批准号:
    2233343
  • 财政年份:
    2023
  • 资助金额:
    $ 45.44万
  • 项目类别:
    Standard Grant
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
  • 批准号:
    2233342
  • 财政年份:
    2023
  • 资助金额:
    $ 45.44万
  • 项目类别:
    Standard Grant
Molecular mechanisms underlying high-affinity and isotype switched antibody responses
高亲和力和同种型转换抗体反应的分子机制
  • 批准号:
    479363
  • 财政年份:
    2023
  • 资助金额:
    $ 45.44万
  • 项目类别:
    Operating Grants
Deconstructed T cell antigen recognition: Separation of affinity from bond lifetime
解构 T 细胞抗原识别:亲和力与键寿命的分离
  • 批准号:
    10681989
  • 财政年份:
    2023
  • 资助金额:
    $ 45.44万
  • 项目类别:
CAREER: Engineered Affinity-Based Biomaterials for Harnessing the Stem Cell Secretome
职业:基于亲和力的工程生物材料用于利用干细胞分泌组
  • 批准号:
    2237240
  • 财政年份:
    2023
  • 资助金额:
    $ 45.44万
  • 项目类别:
    Continuing Grant
ADVANCE Partnership: Leveraging Intersectionality and Engineering Affinity groups in Industrial Engineering and Operations Research (LINEAGE)
ADVANCE 合作伙伴关系:利用工业工程和运筹学 (LINEAGE) 领域的交叉性和工程亲和力团体
  • 批准号:
    2305592
  • 财政年份:
    2023
  • 资助金额:
    $ 45.44万
  • 项目类别:
    Continuing Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了